---
schema_version: "secwatch.filing_event.v1"
accession: "0001610618-24-000074"
form_type: "8-K"
ticker: null
cik: "0001610618"
company_name: "Cidara Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:09:28.298952+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cidara reacquires CD388 flu program, raises $240M; Q1 revenue $8.5M, net loss $10.3M

## Summary
- Reacquired exclusive global development and commercial rights to CD388 from Janssen; plans to initiate Phase 2b trial in upcoming Northern Hemisphere flu season.
- Closed $240.0M private placement led by RA Capital; $85.0M used for upfront Janssen payment, remaining $155.0M funds runway through Phase 2b topline.
- Divested rezafungin to Mundipharma; expects ~$128.0M cost savings over rezafungin patent life.
- Q1 2024 revenue $8.5M (down from $26.1M YoY); net loss $10.3M vs net income $3.0M in prior year period.
- Appointed three new board members (Tadvalkar, Spencer, Merson); executed 1-for-20 reverse stock split, shares trade under CDTX.

## SEC filing metadata
- accession: 0001610618-24-000074
- form_type: 8-K
- cik: 0001610618
- company_name: Cidara Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000074/0001610618-24-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000074/cdtx-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001610618-24-000074
- JSON: https://secwatch.observer/filing/0001610618-24-000074.json
- Plain text: https://secwatch.observer/filing/0001610618-24-000074.txt

## Key facts
- Earnings Releases
  Cidara Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $8.5 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $8.5 million
  - Result: reported results
  source text: Company’s multispecific CD73/PD-1 DFC, its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73. First Quarter 2024 Financial Results • Revenue totaled $8.5 million for the three months ended March 31, 2024, compared to $26.1 million for the same period in 2023. Revenue for the three months ended March 31, 2024 related to the achievement of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000161061824000074/0001610618-24-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.